Slow Release of an LHRH Analog to Reduce Serum Testosterone

  • Debra J. Trantolo
  • Joseph D. Gresser
  • A. Ganiyu Jimoh
  • Donald L. Wise
  • Richard C. RhodesIII
  • Janet E. Hall


During the last several decades, research into neuroendocrine control by LHRH and other hypothalamic hormones has been an area of high activity. Since Schally and Guillemin’s Nobel Prize winning work of the early 1970s, the isolation, determination of structure, and synthesis of hypothalamic peptide hormones, as well as the synthesis of their analogs, have revealed radically new approaches to diagnosis and treatment of endocrine and nonendocrine disorders (1–10). Clinical applications of the hypothalamic hormones include: differentiation between hypothalamic and pituitary lesion, stimulation of fertility, birth control, and treatment of precocious puberty, endometriosis, cryptochidism, diabetes mellitus, acromegaly, and acute pancreatitis. The uses of analogs of hypothalamic hormones for hormone-sensitive tumors is relatively more recent, but of major current clinical value and significance, as evidenced by the quick transfer of basic research results to FDA approvals. LHRH agonist analogs are now used for the treatment of endometriosis and precocious puberty, as well as many of the endocrine-dependent tumors found in prostate cancer, breast cancer, and ovarian cancer.


Polylactic Acid Serum Testosterone Glycolic Acid Precocious Puberty LHRH Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schally AV, Arimuar A, and Coy DH. Recent approaches to fertility control based on derivatives of LHRH, in Vitamins and Hormones 1980; (Munson PL, Glover E, Diczfalusy B, and Olson RE, eds), Academic, New York, 38: 257–323.Google Scholar
  2. 2.
    Schally AV, Coy DH, and Arimuar A. LHRH agonists and antagonists. Int J Gynaecol Obstet 1980; 18: 318–324.Google Scholar
  3. 3.
    Schally AV, and Coy DH. Stimulatory and inhibitory analog of LH-releasing hormone: basic and clinical studies, in Role of Peptides and Proteins in Control of Reproduction 1983; (McCann SM and Dhindsa DS, eds), Elsevier, New York, pp 89–110.Google Scholar
  4. 4.
    Schally AV, Coy DH, and Meyers CA. Hypothalamic regulatory hormones, in Annual Reviews in Biochemistry 1989; (Snell EE, ed), 47: 89–128.Google Scholar
  5. 5.
    Schally AV, Coy DH, Meyers CA, and Kastin AJ. Hypothalamic peptide hormones: basic and clinical studies, in Hormonal Proteins and Peptides 1978; (Li CH, ed), Academic, New York, pp 1–54.Google Scholar
  6. 6.
    Hall R and Gomez-Pan A. The hypothalamic regulatory hormones and their clinical applications. Adv Clin Chem 1976; 18: 173–212.CrossRefGoogle Scholar
  7. 7.
    Grossman A, Kruseman AC, Perry L, Tomlin S, Schally AV, Coy DH, et al. New hypothalamic hormones, CRF, specifically stimulates the release of ACTH and cortiol in man. Lancet 1982; i: 981,982.Google Scholar
  8. 8.
    Thorner MO, Spiess J, Vance ML, Rogol AD, Kaiser DL, Webster JD, et al. Human pancreatic growth-hormone releasing factor selectively stimulates growth-hormone in man Lancet 1983; E24–28.Google Scholar
  9. 9.
    Vale W, Spiess J, Rivier C, and Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and B-endorphin. Science 1981; 213: 1394–1397.CrossRefGoogle Scholar
  10. 10.
    Schally AV. Current status of antagonistic analogs of LHRH as a contraceptive method in the female, PARFR Review: Res Front Fertil Reg 1983; 2: 1–16.Google Scholar
  11. 11.
    Walsh PC. Physiological basis for hormonal therapy in carcinoma of the prostate. Urol Clin N Am 1975; 2: 25–140.Google Scholar
  12. 12.
    Whitmore WJ Jr. Hormone therapy in prostatic cancer. Am JMed 1956; 21: 697–713.Google Scholar
  13. 13.
    Murphy GP. Prostate cancer: continuing progress. Cancer J Clin 1981; 31: 96–110.CrossRefGoogle Scholar
  14. 14.
    Huggins C, Stevens RE, and Hodges CW. Studies on prostatic carcinoma, II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–211.CrossRefGoogle Scholar
  15. 15.
    Huggins C and Hodges CV. Studies of prostatic cancer. I. Effect of castration, estrogens and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–295.Google Scholar
  16. 16.
    Grayhack JT. Pituitary factors influencing growth of the prostate. Nat Cancer Inst Monogr 1962; 12: 189–199.Google Scholar
  17. 17.
    Grayhack JT and Lebowitz JM. Effect of prolactin on citric acid of lateral lobe of prostate of SpragueDawley rats. Invest Urol 1967; 5: 87–94.Google Scholar
  18. 18.
    Schoonees R, Bourke RS, Reynoso G, Murphy GP, and Schaich DS. Hypophysectomy for reactivated disseminated prostatic carcinoma. S Afr Med J 1972; 46: 1278–1285.Google Scholar
  19. 19.
    Lawrence AM and Landau RL. Impaired ventral prostate affinity for testosterone in hypophysectomized rats. Endocrinology 1965; 77: 1119–1125.CrossRefGoogle Scholar
  20. 20.
    Trachtenberg J and Walsh PC. Correlation of pro-static nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 1982; 127: 466–471.Google Scholar
  21. 21.
    Karr JP and Sandberg AA. Steroid receptors and prostatic cancer, in Prostatic Cancer 1979; (Murphy GP, ed), PSG, Littleton, MA, pp 49–75.Google Scholar
  22. 22.
    Hedlund PO, Gustafson H, and Sjogren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyl) or conventional estrogen. A follow-up of 212 randomized patients. Scand J Urol Nephrol Suppl 1980; 55: 103–105.Google Scholar
  23. 23.
    Parmur H, Phillips EL, Allen RH, and Lightman SL. Orchiectomy verus long-setting D-Trp-6LHRH in advanced prostatic cancer. Br J Urol 1987; 59: 248–254.CrossRefGoogle Scholar
  24. 24.
    Fun BJ and Woodburn JR. Luteinizing hormone-release hormone and its analogues: a review of biological properties and clinical uses. JEndocrinol Invest 1988; 11: 535–557.Google Scholar
  25. 25.
    Debruyne FM. Results ofa Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer. Am J Clin Oncol 1988; 1 I (suppl): S33–35.Google Scholar
  26. 26.
    Bloom JHM, Hirdes WH, Schroder FH, deJong FH, Kwekkeboom DJ, van’t Veen AJ, et al. Pharmacokinetics and endocrine effects of the LHRH analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol Res 1989; 17: 43–46.Google Scholar
  27. 27.
    Dijkman GA, Fernandez del Moral P, Plasman JWH, Pull HC, van der Meijden APM, Debruyne FMJ, et al. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot. Eur Urol 1980; 18 (suppl 3): 22–25.Google Scholar
  28. 28.
    Wise DL (ed). Burn Wound Coverings 1984; vols. 1 and 2, CRC, Boca Raton, FL.Google Scholar
  29. 29.
    Wise DL (ed). Biopolymeric Controlled Release Systems 1984; vols. 1 and 2, CRC, Boca Raton, FL.Google Scholar
  30. 30.
    Wise DL and Langer RS. Medical Application of Controlled Release 1984; vols. 1 and 2, CRC, Boca Raton, FL.Google Scholar
  31. 31.
    Wise DL, Reuning RH, Liao SHT, Staubus AE, Aschcraft SB, Downs DA, et al. Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system. J Pharmacokin Biopharmacol 1983; 2: 369–387.Google Scholar
  32. 32.
    Wise DL, Carl Sharon A, Willette RE, and Barnett G (eds), Development of Drug Delivery Systems for Use in Treatment of Narcotic Addiction 1980; National Institute of Drug Abuse, Washington, DC, pp 194–213.Google Scholar
  33. 33.
    Wise DL, Gresser JD, and McCormick GJ. Sustained release of a dual antimalarial system. J Pharm Pharmacol 1979; 31: 201–204.CrossRefGoogle Scholar
  34. 34.
    Wise DL, Fellman TD, Sanderson JE, and Wentworth RL. Lactic/glycolic acid polymers, in Drug Carriers in Biology and Medicine 1979; Academic, New York.Google Scholar
  35. 35.
    Wise DL, Benagiano, G, Schmitt GE, and Goodman M. Sustained release hormonal preparations for the delivery of fertility-regulating agents. J Polymer Sci 1979; (Polymer Symposia) 66: 129–148.Google Scholar
  36. 36.
    Wise DL, McCormick GJ, Willet GP, Anderson LC, and Howes JF. Sustained release of sulphadiazine. JPharm Pharmacol 1978; 30: 686–689.CrossRefGoogle Scholar
  37. 37.
    Wise DL, Schwope AD, Harrigan, S, McCarthy DA, and Howes JF. Sustained delivery of a narcotic antagonist from lactic/glycolic acid copolymer implants, in Polymeric Delivery Systems 1977; Midland Macromolecular Institute Monograph, vol 5, Gordon & Breach, New York.Google Scholar
  38. 38.
    Wise DL and Schwope AD. Evaluation of wound-covering materials. JBiomed MaterRes 1977; 11: 489.CrossRefGoogle Scholar
  39. 39.
    Wise DL, Gregory JB, Newberne PM, Bartholow LC, and Stanburg J. Results in biodegradable cylindrical subdermal implants for fertility control, in Polymeric Delivery Systems 1977; Midland Macro-molecular Institute Monograph, vol 5, Gordon & Breach, New York.Google Scholar
  40. 40.
    Wise DL, McCormick GV, and Willett GP. Sustained release of an anti-malarial drug using a copolymer of glycolic/lactic acid. Life Sci 1976; 19: 867.CrossRefGoogle Scholar
  41. 41.
    Wise DL, Schwope AD, and Howes JF. Development ofPolylactic/Glycolic Acid Delivery Systems for Use in Treatment of Narcotic Addiction 1976; National Institute on Drug Abuse, Research Monograph, vol 4.Google Scholar
  42. 42.
    Wise DL, Anderson LC, and Howes JF. An injectable sustained release fertility control system. Contraception 1976; 13: 375.CrossRefGoogle Scholar
  43. 43.
    Wise DL, Schwope AD, and Howes JF. Lactic/ glycolic polymers as narcotic antagonist delivery systems. Life Sci 1975; 17: 1877.CrossRefGoogle Scholar
  44. 44.
    Wise DL, Schwope AD, Sell KW, Skomick WA, and Dressler DP. Development of a synthetic burn covering. Trans Am Soc ArtifIntern Organs 1974; 20: 103.Google Scholar
  45. 45.
    Wise DL, Jackanics TM, Nash HA, and Gregory JB. Polylactic acid as a biodegradable carrier for contraceptive steroids. Contraception 1973; 8: 227–234.CrossRefGoogle Scholar
  46. 46.
    Schally AF, Comaru-Schally AM, and Redding T. Antitumor effects of analogs of hypothalic hormones in endorine-dependent cancers. Proc Soc Exp Biol Med 1986; 175: 259.Google Scholar
  47. 47.
    Labrie F, DuPont A, Belander A, St. Arnaud R, Giguere M, Lacourciere V, et al. Treatment ofprostate cancer with gonadotropin-releasing hormone agonists. Endo Rev 1986; 7: 67.CrossRefGoogle Scholar
  48. 48.
    Mason-Garcia M, Vigh S, Comaru-Schally AM, Redding TW, Somogyvari-Vigh A, Horvath J, et al. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. Proc Nat 54 Acad Sci USA 1985; 82: 1547.CrossRefGoogle Scholar
  49. 49.
    Hsueh AJW and Jones PBC. Extrapituitary actions of gonadotropin-releasing hormone. Endoc Rev 1981; 2: 437.CrossRefGoogle Scholar
  50. 50.
    Ireland JJ, Aten RF, and Behrin HR. GnRH-like 55 proteins in cows: concentrations during corpora lutea development and selective localization in granulosal cells. Biol Reprod 1988; 38: 544. 56Google Scholar
  51. 51.
    Brown JL and Reeves JJ. Absence of specific luteinizing hormone receptors in ovine, bovine and porcine ovaries. Biol Reprod 1983; 29: 1179. 57Google Scholar
  52. 52.
    Candas BD, LaCoste D, Normand M, and LaBrie F. Model of the distribution and metabolism of the gonadotropin releasing hormone (GnRH) agonist [D-Trp6,Des-Gly-NH210] LHRH ethylamide. J Clin Endocrinol Metab 1990; 70: 1046. 58Google Scholar
  53. 53.
    Rodbard D, Bridson W, and Rayford PL. Calculation of radioimmunoassay results. JLab Clin Med 1969; 74: 770.Google Scholar
  54. 54.
    Brady JM, Cutright DE, Miller RR, and Battistone GC. Resorption rate, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J Biomed Mater Res 1973; 7: 155–166.CrossRefGoogle Scholar
  55. 55.
    Brandt RB, Waters MG, Risplet MJ, and Kline ES. D- and L-lactate catabolism to CO2 in rat tissues. Proc Soc Exp Biol Med 1984; 175: 332–335.Google Scholar
  56. 56.
    Chu CC. Hydrolytic degradation of poly-glycolic acid: tensile strength and crystallinity study. JAppl Polym Sci 1981; 26: 1717–1734.Google Scholar
  57. 57.
    Cutright DE, Perez B, Beasley JD, Larson WJ, and Posey WR. Degradation rates of polymers and copolymers of polylactic and polyglycolic acids. Oral Surg Oral Med Oral Pathol 1974; 37: 142–152.CrossRefGoogle Scholar
  58. 58.
    Csernus VJ, Szende B, and Schally AV. Release of peptides from sustained delivery systems (micro-capsules and microparticles) in vivo. Int JPeptide Prot Res 1990; 35: 557–565.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Debra J. Trantolo
  • Joseph D. Gresser
  • A. Ganiyu Jimoh
  • Donald L. Wise
  • Richard C. RhodesIII
  • Janet E. Hall

There are no affiliations available

Personalised recommendations